Kyntra Bio, Inc. (KYNB): R&D Expense
$23.52M
Year ended 2025-12-31
$22.86M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $23.52M | -75.4% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $95.69M | -64.1% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $266.47M | n/c | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $296.79M | -23.3% | 2024-02-26, From 2022-01-01 |
| 2021-12-31 | $387.04M | +53.0% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $252.92M | +20.9% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $209.26M | -11.3% | 2022-03-04, From 2019-01-01 |
| 2018-12-31 | $235.84M | +20.0% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $196.52M | +5.0% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $187.21M | -12.6% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $214.09M | +42.0% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $150.79M | +75.9% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $85.71M | n/a | 2016-02-29, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $23.52M | -75.4% |
| Filana Therapeutics, Inc. (FLNA) | 2025-12-31 | $26.59M | -61.8% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $38.20M | -1.6% |
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $48.94M | +181.8% |
| PMV Pharmaceuticals, Inc. (PMVP) | 2025-12-31 | $69.88M | +19.4% |
| Sagimet Biosciences Inc. (SGMT) | 2025-12-31 | $39.05M | +1.6% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $50.08M | +105.0% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $12.82M | +207.5% |
| Milestone Pharmaceuticals Inc. (MIST) | 2025-12-31 | $18.11M | +26.1% |
Compare KYNB, FLNA, CAMP, AARD side by side · Screen every company in Pharmaceutical Preparations ↗